Inclusion Criteria:

          -  Participants who have an Eastern Cooperative Oncology Group Performance Status less
             than or equals to (<=) 1

          -  Participants who have histologically confirmed and localized resectable rectal cancer
             (Stage 3)

          -  Participants who received induction chemotherapy are allowed to be enrolled to this
             study except this induction is resulting in clinical complete response (cCR) or tumor
             progression

          -  Participants who have lower edge of the tumor located in rectum

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Male participants if they agree to the following during the study intervention period
             and for at least 12 weeks after the last dose of study intervention

          -  Female participants are eligible if not pregnant or breastfeeding

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with history of any other significant medical disease or psychiatric
             conditions that might in the assessment of the Investigator preclude safe
             participation in the study

          -  Participants with history of difficulty swallowing, malabsorption, or other chronic
             gastrointestinal disease or conditions that may hamper compliance and/or absorption of
             the study intervention

          -  Unstable cardiovascular function within 6 months prior to enrollment

          -  Hypertension uncontrolled by medication (ie, systolic blood pressure >= 150 millimeter
             of mercury (mmHg) and diastolic blood pressure >= 90 mmHg)

          -  Participants with history of other malignant disease within the past 5 years, other
             than successfully treated basal carcinoma of the skin or carcinoma in situ of the
             cervix

          -  Participants with known human immunodeficiency virus positivity, known active
             hepatitis (for example, hepatitis B virus or hepatitis C virus), current alcohol
             abuse, or cirrhosis

          -  Participants with ongoing active infection or treatment with a live attenuated vaccine
             within 4 weeks of dosing

          -  Participants with concomitant use of H2-blocker or proton pump inhibitors (PPIs) (or
             unable to stop at least 5 days prior to the first treatment). Note that calcium
             carbonate is acceptable

          -  Participation in any interventional clinical study within 28 days prior to Screening
             or during participation in this study

          -  Other protocol defined exclusion criteria could apply.